The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

Autor: Gonzalez-Ericsson, Paula, Stovgaard, Elisabeth, Sua, Luz, Reisenbichler, Emily, Kos, Zuzana, Carter, Jodi, Michiels, Stefan, Le Quesne, John, Nielsen, Torsten, Laenkholm, Anne-Vibeke, Fox, Stephen, Adam, Julien, Bartlett, John MS, Rimm, David, Quinn, Cecily, Peeters, Dieter, Dieci, Maria, Vincent-Salomon, Anne, Cree, Ian, Hida, Akira, Balko, Justin, Haynes, Harry, Frahm, Isabel, Acosta-Haab, Gabriela, Balancin, Marcelo, Bellolio, Enrique, Yang, Wentao, Kirtani, Pawan, Sugie, Tomoharu, Ehinger, Anna, Castaneda, Carlos, Kok, Marleen, McArthur, Heather, Siziopikou, Kalliopi, Badve, Sunil, Fineberg, Susan, Gown, Allen, Viale, Giuseppe, Schnitt, Stuart, Pruneri, Giancarlo, Penault-Llorca, Frédérique, Hewitt, Stephen, Thompson, E Aubrey, Allison, Kimberly, Symmans, William, Bellizzi, Andrew, Brogi, Edi, Moore, David, Larsimont, Denis, Dillon, Deborah, Lazar, Alexander, Lien, Huangchun, Goetz, Matthew, Broeckx, Glenn, El Bairi, Khalid, Harbeck, Nadia, Cimino-Mathews, Ashley, Sotiriou, Christos, Adams, Sylvia, Liu, Shi-Wei, Loibl, Sibylle, Chen, I-Chun, Lakhani, Sunil, Juco, Jonathan, Denkert, Carsten, Blackley, Elizabeth, Demaria, Sandra, Leon-Ferre, Roberto, Gluz, Oleg, Zardavas, Dimitrios, Emancipator, Kenneth, Ely, Scott, Loi, Sherene, Salgado, Roberto, Sanders, Melinda, Gonzalez‐Ericsson, Paula, Lænkholm, Anne‐Vibeke, Vincent‐Salomon, Anne, Acosta‐Haab, Gabriela, Penault‐Llorca, Frederique, Cimino‐Mathews, Ashley, Liu, Shi‐wei, Chen, I‐Chun, Leon‐Ferre, Roberto

Publikováno v: Journal of pathology
The journal of pathology
Journal of Pathology
Journal of Pathology, Wiley, 2020, 250 (5), pp.667-684. ⟨10.1002/path.5406⟩
Journal of Pathology, 2020, 250 (5), pp.667-684. ⟨10.1002/path.5406⟩
Gonzalez-Ericsson, P I, S Stovgaard, E, Sua, L F, Reisenbichler, E, Kos, Z, Carter, J M, Michiels, S, Quesne, J L, O Nielsen, T, Laenkholm, A-V, B Fox, S, Adam, J, Bartlett, J, Rimm, D L, Quinn, C, Peeters, D, V Dieci, M, Vincent-Salomon, A, Cree, I, I Hida, A, Balko, J M, Haynes, H R, Frahm, I, Acosta-Haab, G, Balancin, M, Bellolio, E, Yang, W, Kirtani, P, Sugie, T, Ehinger, A, A Castaneda, C, Kok, M, McArthur, H, Siziopikou, K, Badve, S, Fineberg, S, Gown, A, Viale, G, J Schnitt, S, Pruneri, G, Penault-Llorca, F, Hewitt, S, Aubrey Thompson, E, H Allison, K, F Symmans, W, M Bellizzi, A, Brogi, E, A Moore, D, Larsimont, D, A Dillon, D, Lazar, A, Lien, H, P Goetz, M, Broeckx, G, El Bairi, K, Harbeck, N, Cimino-Matthews, A, Sotiriou, C, Adams, S, Liu, S-W, Loibl, S, Chen, I C, Lakhani, S R, W Juco, J, Denkert, C, F Blackley, E, Demaria, S, Leon-Ferre, R, Gluz, O, Zardavas, D, Emancipator, K, Ely, S, Loi, S, Salgado, R & Sanders, M 2020, ' The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice ', The Journal of Pathology .

Immune checkpoint inhibitor therapies targeting PD-1/PD-L1 are now standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::893d70be1cdb1810919fdbad41a96203
https://pubmed.ncbi.nlm.nih.gov/32129476